Analysts Issue Forecasts for MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of MoonLake Immunotherapeutics in a research report issued to clients and investors on Thursday, February 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.81) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.62) EPS.

Other research analysts have also issued reports about the stock. The Goldman Sachs Group reduced their target price on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a report on Thursday. Needham & Company LLC upped their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wedbush restated an “outperform” rating and issued a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $83.20.

MoonLake Immunotherapeutics Trading Down 0.0 %

NASDAQ:MLTX opened at $41.76 on Friday. The firm has a market cap of $2.67 billion, a price-to-earnings ratio of -32.37 and a beta of 1.28. The company’s 50-day moving average is $46.49 and its two-hundred day moving average is $48.91. MoonLake Immunotherapeutics has a 12-month low of $37.55 and a 12-month high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.09).

Institutional Trading of MoonLake Immunotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. increased its position in MoonLake Immunotherapeutics by 3.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company’s stock worth $460,000 after purchasing an additional 320 shares in the last quarter. Deutsche Bank AG grew its position in MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company’s stock valued at $49,000 after acquiring an additional 338 shares in the last quarter. GSA Capital Partners LLP boosted its stake in shares of MoonLake Immunotherapeutics by 1.9% during the 3rd quarter. GSA Capital Partners LLP now owns 22,127 shares of the company’s stock valued at $1,116,000 after buying an additional 403 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of MoonLake Immunotherapeutics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 58,950 shares of the company’s stock valued at $3,192,000 after buying an additional 540 shares during the last quarter. Finally, DnB Asset Management AS lifted its stake in MoonLake Immunotherapeutics by 11.3% during the fourth quarter. DnB Asset Management AS now owns 8,356 shares of the company’s stock worth $452,000 after purchasing an additional 847 shares during the last quarter. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.